TABLE 3.
Cardiometabolic Outcomes
| Cardiometabolic Outcome | Baseline (N = 45) | Post-Program (N = 35)a | 6 Months (N = 34)a | 12 Months (N = 23)a | Ptrendb |
|---|---|---|---|---|---|
| Blood glucose (mg/dL)c | 100.7 (19.5) | 99.9 (18.3) | 107.1 (20.7) | 106.9 (26.3) | 0.34 |
| Diabetes at baseline (n = 9) | 127.4 (20.8) | 120.6 (26.4) | 127.6 (21) | 141.2 (31.9) | 0.55 |
| Blood glucose <100 mg/dLc (n, %) | 24 (63.2) | 20 (64.5) | 10 (35.7) | 11 (52.4) | 0.52 |
| LDL-C (mg/dL)c | 110.2 (33.3) | 109.3 (25.9) | 111 (37.7) | 98.3 (28.3) | 0.43 |
| Baseline LDL-C >130 mg/dL (n = 10) | 151.2 (18) | 122 (28.4)* | 150 (38) | 115.6 (27.2)** | 0.08 |
| LDL-C <100 mg/dLc (n, %) | 12 (36.4) | 10 (38.5) | 12 (44.4) | 11 (52.4) | 0.07 |
Note. LDL-C = low-density lipoprotein cholesterol.
a
35 participants had both baseline and post-program assessment; 34 participants had both baseline and 6-month assessment; 23 participants had both baseline and 12-month assessment.
b
The mixed models were used to account for repeated measurements in the four different sites at the four time points.
c
Missing information: glucose at baseline (n = 7), post-program (n = 4), 6 months (n = 6), and 12 months (n = 2); LDL-C at baseline (n = 12), post-program (n = 9), 6 months (n = 7), and 12 months (n = 2).
*
p < 0.05;
**
p < 0.01 for adjusted p values compared with baseline data.